145 related articles for article (PubMed ID: 35550030)
1. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.
Hwang JH; Arafeh R; Seo JH; Baca SC; Ludwig M; Arnoff TE; Sawyer L; Richter C; Tape S; Bergom HE; McSweeney S; Rennhack JP; Klingenberg SA; Cheung ATM; Kwon J; So J; Kregel S; Van Allen EM; Drake JM; Freedman ML; Hahn WC
Elife; 2022 May; 11():. PubMed ID: 35550030
[TBL] [Abstract][Full Text] [Related]
2. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.
Hwang JH; Seo JH; Beshiri ML; Wankowicz S; Liu D; Cheung A; Li J; Qiu X; Hong AL; Botta G; Golumb L; Richter C; So J; Sandoval GJ; Giacomelli AO; Ly SH; Han C; Dai C; Pakula H; Sheahan A; Piccioni F; Gjoerup O; Loda M; Sowalsky AG; Ellis L; Long H; Root DE; Kelly K; Van Allen EM; Freedman ML; Choudhury AD; Hahn WC
Cell Rep; 2019 Nov; 29(8):2355-2370.e6. PubMed ID: 31747605
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
7. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
Jin HJ; Zhao JC; Wu L; Kim J; Yu J
Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
[TBL] [Abstract][Full Text] [Related]
8. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
9. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.
Rotinen M; You S; Yang J; Coetzee SG; Reis-Sobreiro M; Huang WC; Huang F; Pan X; Yáñez A; Hazelett DJ; Chu CY; Steadman K; Morrissey CM; Nelson PS; Corey E; Chung LWK; Freedland SJ; Di Vizio D; Garraway IP; Murali R; Knudsen BS; Freeman MR
Nat Med; 2018 Dec; 24(12):1887-1898. PubMed ID: 30478421
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 in prostate cancer.
Dong HY; Ding L; Zhou TR; Yan T; Li J; Liang C
Asian J Androl; 2023; 25(3):287-295. PubMed ID: 36018068
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
Zadra G; Ribeiro CF; Chetta P; Ho Y; Cacciatore S; Gao X; Syamala S; Bango C; Photopoulos C; Huang Y; Tyekucheva S; Bastos DC; Tchaicha J; Lawney B; Uo T; D'Anello L; Csibi A; Kalekar R; Larimer B; Ellis L; Butler LM; Morrissey C; McGovern K; Palombella VJ; Kutok JL; Mahmood U; Bosari S; Adams J; Peluso S; Dehm SM; Plymate SR; Loda M
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):631-640. PubMed ID: 30578319
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
15. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.
He Y; Lu J; Ye Z; Hao S; Wang L; Kohli M; Tindall DJ; Li B; Zhu R; Wang L; Huang H
Nucleic Acids Res; 2018 Feb; 46(4):1895-1911. PubMed ID: 29309643
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
[TBL] [Abstract][Full Text] [Related]
19. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
[TBL] [Abstract][Full Text] [Related]
20. Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
Hankey W; Chen Z; Wang Q
Cancer Res; 2020 Jun; 80(12):2427-2436. PubMed ID: 32094298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
